Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(94 sites)

Belgium

Institut Jules Bordet, Anderlecht

AZ KLINA, Brasschaat

Cliniques Universitaires Saint-Luc, Brussels

Grand Hopital de Charleroi - Site Notre Dame, Charleroi

CHU Helora Pole Hospitalier Jolimont - Hopital Jolimont, Haine-Saint-Paul